Skip to main content
Clinical Trials/JPRN-jRCT1071210053
JPRN-jRCT1071210053
Recruiting
N/A

A prospective observational study of the effect of ANamorelin Administration on combined immunochemotherapy in patients with non-small cell lung cancer - SPIRAL-ANA study

chino Junji0 sites127 target enrollmentAugust 24, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
non-small cell lung cancer
Sponsor
chino Junji
Enrollment
127
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 24, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
chino Junji

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients aged 20 or older at the time of informed consent).
  • 2\) Patients who are to receive combined immunochemotherapy and who are to receive anamorelin 7 days prior to and on the same day as the first dose.
  • 3\) Patients with histologically or cytologically confirmed non\-small cell lung cancer.
  • 4\) Patients with Stage III/IV or postoperative recurrence who are not eligible for radical radiation therapy or resection.
  • 5\) Patients with positive driver gene should be treated with kinase inhibitors.
  • 6\) Patients who have not been treated with cell\-killing anticancer agents for advanced stage or postoperative recurrence lung cancer. However, preoperative and postoperative adjuvant chemotherapy is acceptable.
  • 7\) Patients who meet the criteria for administration of anamorelin.
  • Patients with weight loss of 5% or more and anorexia within 6 months, and at least 2 of the following (1\) to (3\)
  • (1\) Fatigue or malaise
  • (2\) General muscle weakness

Exclusion Criteria

  • 1\) Patients with contraindications to anamorelin administration.
  • (1\) Patients with congestive heart failure
  • (2\) Patients with myocardial infarction or angina pectoris
  • (3\) Patients with severe stimulation conduction system disorder (e.g. complete atrioventricular block)
  • (4\) Patients receiving the following drugs: clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, telaprevir, voriconazole, ritonavir\-containing products, cobicistat\-containing products.
  • (5\) Patients with moderate or severe hepatic dysfunction (Child\-Pugh classification B and C)
  • (6\) Patients with a history of hypersensitivity to any component of anamorelin.
  • (7\) Patients with difficulty in oral intake of food due to organic abnormalities of the gastrointestinal tract such as gastrointestinal obstruction.
  • 2\) Patients with poorly controlled diabetes mellitus.
  • 3\) Patients with intractable nausea and vomiting, chronic gastrointestinal disorders, inability to swallow preparations, or a history of gastrectomy or other procedures that may significantly affect the absorption of anamorelin.

Outcomes

Primary Outcomes

Not specified

Similar Trials